Comparing the current results to its competitors, Summit Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.4 %, recorded in the same quarter.
Summit Therapeutics Inc 's Comment on Competition and Industry Peers
The oncology pharmaceuticals market is characterized by significant scientific innovation, regulatory oversight, and intense competition. Key factors for success include efficacy, safety, convenience, price, and coverage or reimbursement availability. Competitors often possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Smaller or early-stage companies may also compete effectively, particularly through collaborations with large, established firms. Competition extends to recruiting qualified personnel, establishing clinical trial sites, patient registration, and acquiring complementary technologies. The company's commercial opportunities may be reduced or eliminated if competitors, such as Akeso, develop safer, more effective, more convenient, or less expensive products or obtain marketing approvals more rapidly.
November 7, 2025
As the landscape of cancer therapy continues to evolve, recent advancements in bispecific antibody treatments are capturing the spotlight. One such innovation is ivonescimab, an investigational antibody that has demonstrated a significant breakthrough in the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. In a watershed moment for both its developer Akeso and its partner, Summit Therapeutics Inc., data from the Phase III HARMONi-A study have led to a pivotal declaration: patients receiving ivonescimab alongside chemotherapy exhibited a hazard ratio of 0.74, translating to a statistically significant enhancement in overall survival rates.The impressive results ...
October 17, 2025
Summit Therapeutics Inc. (NASDAQ: SMMT) has announced a significant advancement in its clinical portfolio with the launch of the global Phase III HARMONi-GI3 trial. This study will investigate the efficacy of the investigational bispecific antibody ivonescimab in combination with chemotherapy for the treatment of patients with first-line colorectal cancer (CRC). The initiation of this trial marks an important step in Summit s efforts to establish ivonescimab as a potentially first-in-class therapeutic option for CRC patients.The HARMONi-GI3 study will pit the ivonescimab-chemo regimen against the well-established bevacizumab plus chemotherapy. By comparing these two treatment approaches, Summit aims not only...
September 8, 2025
Title : Emerging Trends in Lung Cancer Treatment: Phase III HARMONi Trial Reveals Promising Results for Ivonescimab Plus Chemotherapy:In a significant advancement in oncology, Summit Therapeutics Inc. (NASDAQ: SMMT) has unveiled new data from the global Phase III HARMONi clinical trial evaluating the efficacy of the novel bispecific antibody, ivonescimab. The drug is a potential first-in-class treatment being tested in combination with chemotherapy for patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) in second-line and later settings. The promising results were presented during the prestigious Presidential Symposium at the International Association for the Stu...
October 3, 2024
In a significant stride towards advancing cancer treatment, Summit Therapeutics Inc. (NASDAQ: SMMT) has announced the successful completion of patient enrollment in its pivotal Phase III HARMONi clinical trial. This multi-regional study is designed to evaluate the efficacy of ivonescimab in conjunction with platinum-doublet chemotherapy, compared to a placebo with the same chemotherapy regimen, in patients diagnosed with epidermal growth factor receptor (EGFR)-mutated, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC) who have experienced progression following prior therapies.The HARMONi trial comes at a crucial time in the ongoing fight against NSCLC, a notoriously challenging ...
July 25, 2024
The landscape of cancer therapy continues to evolve with the emergence of advanced therapeutics. A notable example is ivonescimab, a potential first-in-class PD-1/VEGF bispecific antibody. Summit Therapeutics Inc. and The University of Texas MD Anderson Cancer Center have embarked on a strategic collaboration aimed at accelerating the development of ivonescimab. This article delves into the key aspects of this partnership and highlights recent clinical advancements, including publication results from the HARMONi-A clinical trial. As cancer remains one of the leading causes of morbidity and mortality worldwide, the need for innovative treatments is paramount. Recent advancements in immunotherapy have se...
June 1, 2024
Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit or the Company) announced that on May 24, 2024, their partner Akeso Inc. (HKEX Code: 9926.HK) received marketing authorization in China for ivonescimab (SMT112) in combination with chemotherapy for the treatment of second-line and beyond (2L+) Epidermal Growth Factor Receptor-mutated non-small cell lung cancer (EGFRm NSCLC). This approval, granted by the National Medical Products Administration (NMPA), is based on the positive results from the HARMONi-A clinical trial. Ivonescimab (SMT112) is an innovative therapeutic agent characterized as a first-in-class bispecific antibody. It exerts its effects through a dual mechanism by simultaneously blocking Programm...
Nexien Biopharma Inc operates as a biotechnology company focused on the development and commercialization of innovative therapies for various medical conditions. They aim to use their expertise in biopharmaceutical research to bring novel treatments to market, improving patient outcomes and meeting unmet medical needs.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Sources:
Summit Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Summit Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
